Aripiprazole Long-Acting Injection (Abilify Maintena)
Complete guide to Abilify Maintena: dosing, administration, uses, and side effects.
About Aripiprazole Long-Acting Injection
Abilify Maintena is a long-acting injectable formulation of aripiprazole, an atypical antipsychotic medication. The medication is administered once monthly via intramuscular injection and is indicated for the treatment of schizophrenia in adults and maintenance monotherapy treatment of bipolar I disorder in adults. Unlike oral aripiprazole, which requires daily dosing, Abilify Maintena provides prolonged therapeutic concentrations of the medication through a slow-release mechanism over approximately four weeks. This extended-release formulation is designed to improve medication adherence and reduce the frequency of administration compared to traditional oral antipsychotic medications.
What Is Abilify Maintena Used For?
Abilify Maintena is prescribed for the maintenance treatment of two primary mental health conditions:
- Schizophrenia: Used for the treatment of schizophrenia in adults whose disease has already been stabilized with oral aripiprazole. The long-acting formulation helps prevent relapse of psychotic symptoms and maintains symptom control over extended periods.
- Bipolar I Disorder: Approved for maintenance monotherapy treatment of bipolar I disorder in adults. This application helps prevent the recurrence of mood episodes in patients with bipolar disorder.
The medication is specifically designed for patients whose condition has been stabilized with oral antipsychotic therapy, ensuring tolerability before transitioning to the long-acting injectable form.
How Does Abilify Maintena Work?
Aripiprazole functions as an atypical antipsychotic by acting as a partial agonist at dopamine D2 receptors and serotonin 5-HT1A receptors in the brain. This mechanism of action helps normalize neurotransmitter activity associated with psychotic and mood symptoms. When formulated as Abilify Maintena, the active ingredient is suspended in a prolonged-release formulation that slowly releases aripiprazole into the bloodstream over approximately four weeks following intramuscular injection. This sustained-release mechanism maintains therapeutic plasma concentrations throughout the dosing interval, reducing the need for daily oral medication adherence.
Before You Start Treatment
Before initiating Abilify Maintena therapy, several important considerations and requirements must be addressed:
Establishing Tolerability
Patients who are naive to aripiprazole must establish tolerability with oral aripiprazole prior to receiving their first Abilify Maintena injection. This period allows healthcare providers to assess how the patient responds to aripiprazole and identify any adverse reactions. Due to the half-life of oral aripiprazole, it may take up to two weeks to fully assess tolerability. This prerequisite ensures that patients will not experience serious adverse effects when switching to the long-acting formulation.
Medical History Assessment
Healthcare providers will review your complete medical history, including:
- Current medications and supplements, particularly those affecting cytochrome P450 metabolism
- History of cardiovascular conditions
- Seizure disorders or conditions lowering seizure threshold
- Diabetes or metabolic syndrome
- Neuroleptic malignant syndrome (NMS) history
- Tardive dyskinesia or other movement disorders
- Orthostatic hypotension or syncope
Dosage and Administration
Standard Dosing
The recommended starting and maintenance dose of Abilify Maintena is 400 mg administered monthly (no sooner than 26 days after the previous injection) as a single intramuscular injection. The dose may be reduced to 300 mg in patients who experience adverse reactions. For patients in specific populations, such as those who are cytochrome P450 (CYP) poor metabolizers, dosage adjustments may be necessary.
Two Initiation Regimens
The starting dose can be administered following one of two regimens, each designed to establish therapeutic aripiprazole concentrations during the initiation phase:
| Regimen | Administration | Oral Supplementation |
|---|---|---|
| One Injection Start | One 400 mg injection of Abilify Maintena | 10-20 mg oral aripiprazole daily for 14 consecutive days |
| Two Injection Start | Two separate 400 mg injections at different injection sites | One 20 mg dose of oral aripiprazole on the same day |
The two-injection start regimen is not recommended for patients who are known cytochrome P450 CYP2D6 poor metabolizers and concurrently use a strong CYP3A4 inhibitor.
Injection Site and Administration
Abilify Maintena is administered by a healthcare professional only as an intramuscular injection into either the deltoid (shoulder) or gluteal (buttock) muscle. The injection must not be administered intravenously or subcutaneously. The medication is supplied as a powder and solvent that must be reconstituted into a prolonged-release suspension immediately before injection. Healthcare professionals must follow proper aseptic technique and standard intramuscular injection procedures during administration.
Dosage Adjustments
Dosage adjustments are recommended in specific clinical situations:
- CYP2D6 Poor Metabolizers: Reduced dosages are necessary for patients with reduced cytochrome P450 metabolism capacity.
- Adverse Reactions: If the 400 mg dosage produces adverse reactions, the dose may be reduced to 300 mg once monthly.
- Enzyme Inhibitors and Inducers: Special considerations apply when patients use medications that inhibit or induce CYP3A4 or CYP2D6 enzymes.
Missed Doses
If a scheduled Abilify Maintena injection is missed, the management depends on the time elapsed since the last injection:
- If 5 weeks or less have elapsed: Administer the injection as soon as possible.
- If more than 5 weeks have elapsed (for doses 1-3): Restart concomitant oral aripiprazole for 14 days with the next administered injection.
- If 4-6 weeks have elapsed (for doses 4 and beyond): Administer the injection as soon as possible.
- If 6 weeks or more have elapsed: Restart concomitant oral aripiprazole for 14 days with the next administered injection.
How to Use This Medicine
Preparation and Administration
Abilify Maintena comes as a powder in single-dose packs that contain a vial of powder along with a solvent. A healthcare professional must reconstitute the medication by mixing the powder with the solvent according to package instructions immediately before administration. The reconstituted suspension is then drawn into an appropriate syringe and administered as a deep intramuscular injection into either the deltoid or gluteal muscle. Patients should allow the healthcare provider to select the appropriate injection site based on muscle mass and clinical assessment.
Patient Responsibilities
While Abilify Maintena requires administration by a healthcare professional, patients have important responsibilities in their treatment:
- Attend all scheduled injection appointments on a monthly basis (no sooner than 26 days after the previous injection)
- Inform healthcare providers of any side effects or concerns between injections
- Continue taking any prescribed oral aripiprazole during the 14-day initiation period
- Report any missed doses promptly
- Maintain regular mental health assessments and follow-up appointments
Possible Side Effects
Common Side Effects
Many patients experience side effects when using Abilify Maintena. Common side effects include restlessness (akathisia), drowsiness or sedation, and pain or discomfort at the injection site. Most common adverse effects are mild to moderate and may improve with continued use as the body adjusts to the medication.
Other Reported Side Effects
Additional side effects that patients may experience include:
- Tremor or muscle rigidity
- Headache
- Insomnia or sleep disturbances
- Anxiety
- Nausea or gastrointestinal upset
- Weight gain
- Metabolic changes including elevated cholesterol or blood glucose
- Orthostatic hypotension (dizziness upon standing)
Temperature Regulation and Precautions
Abilify Maintena can affect your body’s ability to regulate temperature. Patients should try to avoid getting overheated, stay well hydrated, and wear light and breathable clothing while using this medication. Avoid strenuous exercise during hot weather and be cautious in environments where overheating is likely.
Alertness and Coordination
Abilify Maintena can affect alertness and coordination. Patients should avoid driving, operating machinery, or engaging in potentially hazardous activities until they understand how the medication affects them. Alcohol should be avoided as it may increase drowsiness and impair judgment.
Important Safety Information
Efficacy and Effectiveness
Clinical evidence demonstrates that Abilify Maintena is as effective as oral aripiprazole at preventing symptoms of schizophrenia from returning. In one main study involving adults whose disease had already been stabilized with oral aripiprazole, 8.3% of patients treated with Abilify Maintena experienced symptom relapse within 26 weeks, compared with 7.9% of patients treated with oral aripiprazole, indicating comparable efficacy. The primary advantage is improved adherence due to the monthly dosing schedule rather than daily oral medication.
Safety Profile
Abilify Maintena has a similar safety profile to oral aripiprazole, with the exception of injection pain, which is considered manageable. Serious adverse effects are rare but may include neuroleptic malignant syndrome (NMS), tardive dyskinesia, and increased mortality in elderly patients with dementia-related psychosis.
Advantages Over Oral Formulations
Abilify Maintena offers several significant advantages compared to daily oral antipsychotic medications:
- Improved Adherence: Monthly injections eliminate the need for daily medication adherence, reducing the risk of missed doses.
- Consistent Therapeutic Levels: The prolonged-release formulation maintains stable plasma concentrations throughout the four-week dosing interval.
- Reduced Symptom Relapse: Improved adherence translates to better symptom control and reduced relapse rates.
- Simplified Treatment Regimen: One monthly appointment replaces daily medication management.
- Better Tolerability Assessment: The initial oral supplementation period allows for careful monitoring before full transition to the injectable.
Alternative Long-Acting Formulations
In addition to Abilify Maintena, the FDA has approved Abilify ASIMTUFII, a once-every-two-months aripiprazole long-acting injectable formulation. This newer option offers 960 mg and 720 mg prefilled syringes that deliver sustained plasma concentrations comparable to Abilify Maintena, resulting in comparable safety and efficacy while extending the dosing interval to eight weeks. This formulation may benefit patients who prefer less frequent injections or have difficulty attending monthly appointments.
Frequently Asked Questions
Q: How often do I need to receive Abilify Maintena injections?
A: Abilify Maintena is administered once monthly (no sooner than 26 days after the previous injection) as a single intramuscular injection. This consistent monthly schedule helps maintain therapeutic medication levels and improve treatment adherence.
Q: Do I need to take oral medication after my first Abilify Maintena injection?
A: Yes, after your first Abilify Maintena injection, you will continue oral aripiprazole (10-20 mg daily) or your current antipsychotic for 14 consecutive days to maintain therapeutic antipsychotic concentrations during the initiation phase of therapy.
Q: What happens if I miss a scheduled injection?
A: If you miss an injection, contact your healthcare provider immediately. Management depends on how much time has elapsed. If more than 5-6 weeks have passed, you may need to restart oral aripiprazole supplementation with your next injection.
Q: Can Abilify Maintena be injected intravenously?
A: No, Abilify Maintena must only be administered by intramuscular injection into the deltoid or gluteal muscle. It must never be injected intravenously or subcutaneously, as this could cause serious adverse effects.
Q: Will I gain weight on Abilify Maintena?
A: Weight gain is a potential side effect of aripiprazole. Regular monitoring of weight, dietary habits, and exercise patterns is recommended. Your healthcare provider can help manage metabolic side effects through lifestyle modifications or medication adjustments if necessary.
Q: Can I drive or operate machinery while taking Abilify Maintena?
A: Abilify Maintena can affect alertness and coordination. You should avoid driving or operating machinery until you understand how the medication affects you. Discuss any concerns with your healthcare provider before engaging in potentially hazardous activities.
Q: How long does it take for Abilify Maintena to work?
A: Abilify Maintena provides sustained therapeutic concentrations over four weeks. However, the initial 14-day period of oral aripiprazole supplementation helps establish therapeutic levels more quickly. Full effects may be evident within the first month of treatment.
References
- Guidelines for the use of Aripiprazole LAI — KMPT Formulary (NHS). December 2021. https://www.kmptformulary.nhs.uk/media/1106/guidelines-for-the-use-of-aripiprazole-lai-dec-21.pdf
- ABILIFY MAINTENA Prescribing Information — U.S. Food and Drug Administration (FDA). 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202971s013lbl.pdf
- Abilify Maintena: European Medicines Agency Assessment Report — European Medicines Agency (EMA). https://www.ema.europa.eu/en/medicines/human/EPAR/abilify-maintena
- FDA Approves ABILIFY ASIMTUFII (aripiprazole) LAI — Otsuka Pharmaceutical U.S., Inc. and H. Lundbeck A/S. https://otsuka-us.com/news/fda-approves-otsuka-and-lundbecks-abilify-asimtufiir-aripiprazole-first-once-every-two-months
- Abilify Maintena (aripiprazole): Uses, Side Effects, and More — WebMD. https://www.webmd.com/drugs/2/drug-163617/abilify-maintena-intramuscular/details
Similar Articles
Read full bio of Sneha Tete
